$7.83
-0.34 (-4.16%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LONA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 4 with posted results
Held by 4 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC) · FINRA short interest 2.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationNCT05696626Progression free survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Metastatic Breast Cancer | 600 | Apr 2027 | ≤ 253 d | 2026-06-22 |
| A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105NCT06432647Incidence of Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · Other | Phase 1 | Completed | Drug: ATH-1105, Placebo | Healthy Volunteers | 80 | 2024-11-25actual | — | 2025-01-23 |
| Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseNCT04886063results2025-04-01Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: ATH-1017-AD-0203 was terminated after the Ph2/3 parent trial (LIFT-AD; NCT04488419) did not meet its primary endpoint, the GST score. | Drug: ATH-1017 | Alzheimer Disease | 423 | 2024-10-23actual | — | 2025-04-01 |
| ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseNCT04488419results2025-04-04Global Statistical Test (GST) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: ATH-1017, Placebo | Alzheimer Disease, Dementia of Alzheimer Type | 554 | 2024-07-15actual | — | 2025-04-04 |
| ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)NCT04831281results2025-03-04Global Statistical Test (GST) Score at BaselineRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Enrollment ended early due to study design limitations. | Drug: ATH-1017, Placebo | Parkinson Disease Dementia, Dementia With Lewy Bodies | 28 | 2023-04-19actual | — | 2025-03-04 |
| A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)NCT05511558Mass balance of total radioactivity from [14C]-FosgonimetonOpen-label · Treatment | Phase 1 | Completed | Drug: [14C]-Fosgonimeton | Healthy Volunteers | 8 | 2022-10-18actual | — | 2022-12-22 |
| Safety, Tolerability, and Pharmacokinetics Study of ATH-1020NCT05169671Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ATH-1020, Placebo | Healthy Volunteers | 32 | 2022-09-09actual | — | 2024-04-08 |
| A Study of ATH-1017 in Mild to Moderate Alzheimer's DiseaseNCT04491006results2023-06-12Event-related Potential (ERP) P300 Latency at BaselineRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ATH-1017, Placebo | Alzheimer Disease, Dementia of Alzheimer Type | 77 | 2022-05-20actual | — | 2023-06-12 |
| Safety, Tolerability, and Pharmacokinetics Study of NDX-1017NCT03298672Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NDX-1017, Placebo | Alzheimer Disease | 88 | 2019-09-05actual | — | 2019-09-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19